Medivir Interim Report, January 1 - June 30, 2001.Business Editors/Medical Writers HUDDINGE, Sweden--(BUSINESS WIRE)--July 6, 2001 Medivir AB -- Profit after financial items was SEK -68.0 (-33.9) m; net sales increased to SEK 63.6 (54.7) m. -- CCS lifted its net sales to SEK 63.8 (41.2) m; operating profit was SEK 9.7 (8.7) m. -- Herpes antiviral ME-609: Final Report from the phase II clinical trial showed good efficacy. Strategy for outlicensing and phase III clinical trial strategy established. -- Multiresistant-HIV antiviral MIV-310: Authorization to commence phase II clinical trials received. -- Good progress in the preclinical portfolio. Forthcoming Reports in 2001 The nine-month Interim Report will be published on 31 October. These Reports will be available on Medivir's Website www.medivir.se on these dates under the heading 'Financial Information'. The Medivir group The group comprises Medivir AB, the subsidiaries Medivir UK Ltd. and CCS (1) (Common Channel Signaling) A communications system in which one channel is used for signaling and different channels are used for voice/data transmission. Signaling System 7 (SS7) is a CCS system, also known as CCS7. See SS7. AB, plus second-tier subsidiaries CCS (UK) Ltd. and Nordic Care Sweden AB (formerly Jillprodukter). Medivir is an innovative specialist pharmaceuticals research and development corporation. Medivir's research is focused on developing compounds into new pharmaceuticals based on proteases and polymerases as target enzymes. Medivir's research concentrates primarily on infectious diseases infectious diseases: see communicable diseases. and autoimmune disorders Autoimmune Disorders Definition Autoimmune disorders are conditions in which a person's immune system attacks the body's own cells, causing tissue destruction. . The research portfolio comprises projects against HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , viral hepatitis viral hepatitis n. Any of various forms of hepatitis caused by a virus. viral hepatitis, n an inflammatory condition of the liver, caused by the hepatitis viruses: A, B, C, delta, E, F, G, or H. , shingles shingles: see herpes zoster. shingles or herpes zoster Acute viral skin and nerve infection. Groups of small blisters appear along certain nerve segments, most often on the back, sometimes after a dull ache at the site; pain becomes , cold sores, osteoporosis and autoimmune disorders. Medivir has five projects in clinical development phases, two of which are entering phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA after completing phase II. Two are in phase I and one project is entering phase II. Medivir's preclinical research encompasses a number of projects, of which two are in their lead optimization phase and one is entering the late preclinical stage. This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.bit.se/bitonline/2001/07/06/20010706BIT00240/bit0002.doc http://www.bit.se/bitonline/2001/07/06/20010706BIT00240/bit0002.pdf |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion